TRANSCRIPTIONAL ANALYSIS OF ZINC-DEPENDENT HISTONE DEACETYLASES IN SEVERAL HUMAN CANCER CELLS

Area of Science:

• Biochemistry
• Molecular Biology
• Cancer Research

Background:

• Histone deacetylases (HDACs), particularly zinc-dependent enzymes, are recognized as promising therapeutic targets for cancer treatment.
• Understanding HDAC expression patterns is crucial for developing effective HDAC inhibitor-based therapies.

Purpose of the Study:

• To investigate the expression levels of various HDAC isoforms across several human cancer cell lines.
• To determine the correlation between HDAC expression profiles and cellular sensitivity or resistance to selective or pan-HDAC inhibitors.

Main Methods:

• Semiquantitative reverse transcription-polymerase chain reaction (RT-PCR) was employed to analyze the RNA expression of 11 HDAC isoforms.
• Cellular sensitivity and resistance to pan- and selective-HDAC inhibitors were assessed using the MTS assay.

Main Results:

• HDAC Class I (HDAC1, 2, 3) and Class II (HDAC4, 5, 6, 7) isoforms exhibited varying expression levels across the studied cell lines.
• No single HDAC subtype demonstrated dominant gene transcription in the analyzed cancer cell lines.
• Pan-HDAC inhibitors displayed superior antitumor activity compared to HDAC isoform-selective inhibitors.

Conclusions:

• The absence of a dominant HDAC subtype transcription profile in diverse human cancer cell lines underlies the reduced efficacy of isoform-selective HDAC inhibitors.
• These findings support the use of pan-HDAC inhibitors over isoform-selective agents for broader anticancer effects.